Psyence Biomedical(NASDAQ) PBM

Market Cap$11.25M

Since IPO (2021)-100%

5 YearN/A

1 Year-95%

1 Month+7%

$3.04

+3.05%

+0.09Today

Psyence Biomedical last closing stock price
Metric	Price	Date
Last close	USD 2.95	2026-07-24

Psyence Biomedical stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.91%	USD 3.07	2026-07-17
1 month	+7.27%	USD 2.75	2026-06-24
3 month	-62.71%	USD 7.91	2026-04-24
Year to date	-37.35%	USD 4.71	2025-12-31
1 year	-95.28%	USD 62.44	2025-07-24
Since inception	-99.99%	USD 36,985.88	2021-12-10

Psyence Biomedical Financials at a Glance

Market Cap

$11.25M

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.25M

EPS (TTM)

$0.00

P/E Ratio

-18.68

Dividend

$0.00

Beta (Volatility)

1.90 (High)

Dividend

$0.00

Beta (Volatility)

1.90 (High)

Price

$3.04

Volume

32,251

Open

$2.99

Price

$3.04

Volume

32,251

Open

$2.99

Previous Close

$3.04

Daily Range

$2.85 - $3.04

52-Week Range

$1.92 - $68.53

Estimated Earnings Date

Jun 24, 2026

Dividend

$0.00

Beta (Volatility)

1.90 (High)

Price

$3.04

Volume

32,251

Open

$2.99

Previous Close

$3.04

Daily Range

$2.85 - $3.04

52-Week Range

$1.92 - $68.53

Estimated Earnings Date

Jun 24, 2026

PBM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Psyence Biomedical

Psyence Biomedical Ltd. is focused on advancing psychedelic medicines derived from botanical psilocybin. The company is exploring natural psilocybin as a potential therapy for adjustment disorder in patients with incurable cancer undergoing palliative care.

Products and Services

PEX010: A psilocybin-based capsule in Phase IIb clinical trials
Psilocybin-assisted psychotherapy for adjustment disorder
Strategic alliance with PsyLabs for Ibogaine manufacturing

Growth Outlook

Partnership with iNGENu for clinical trials enhances research capabilities
Focus on palliative care positions the company in a growing market
Potential expansion into other mental health conditions beyond cancer

Financial Highlights

Recent quarterly net income of -$753,254 indicates ongoing investment in R&D
Cash and short-term investments of $7.2 million provide operational runway
Current ratio of 14.62 suggests strong liquidity position

AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Neil Maresky, MD

Website

psyence.com

Headquarters

Toronto, ON M5H2K1, CA

PBM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-58.62%

Return on Capital

-36.81%

Return on Assets

-39.48%

Earnings Yield

-5.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.25M

Shares Outstanding

3.81M

Volume

32.25K

Avg. Volume

131.05K

Financials (TTM)

Gross Profit

-$2.35K

Operating Income

-$3.47M

EBITDA

-$2.11M

Operating Cash Flow

-CA$1.05M

Capital Expenditure

-CA$7.80

Free Cash Flow

-CA$1.05M

Cash & ST Invst.

$7.20M

Total Debt

$0.00

Psyence Biomedical Performance Analysis

Psyence Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2024	2024-03-31	USD 0	N/A
2025	2025-03-31	USD 0	N/A
2026	2026-03-31	USD 0	N/A

Psyence Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2023-09-30	N/A
Q3	2023-12-31	N/A
Q2	2024-09-30	N/A
Q2	2025-09-30	N/A

Psyence Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 1.53	-2.6%
2024	2024-03-31	USD -49.06	N/A
2025	2025-03-31	USD 1.40	N/A
2026	2026-03-31	USD -12.56	N/A

Psyence Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2023-09-30	-979.5%
Q3	2023-12-31	-2097.1%
Q2	2024-09-30	N/A
Q2	2025-09-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.33K

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.25M

N/A

Market Cap/Employee

$937.69K

N/A

Employees

N/A

Net Income

-$753.25K

-1098.6%

EBITDA

-$749.17K

-799.9%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$7.20M

+73325.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$174.19K

+159.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-39.48%

N/A

Return on Invested Capital

-36.81%

N/A

Free Cash Flow

-$665.00

+99.2%

Operating Cash Flow

-$662.00

+99.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NKGNNKGen Biotech, Inc. Common Stock

NKGNNKGen Biotech, Inc. Common Stock$0.06+0.00%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.06+0.00%

INDPIndaptus Therapeutics, Inc.

INDPIndaptus Therapeutics, Inc.$2.04-21.84%

GTBPGT Biopharma, Inc.

GTBPGT Biopharma, Inc.$0.33+3.02%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$0.92+2.21%

DRMADermata Therapeutics, Inc.

DRMADermata Therapeutics, Inc.$1.29-2.27%

PTIXProtagenic Therapeutics, Inc.

PTIXProtagenic Therapeutics, Inc.$0.22-24.34%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.88+0.03%

ONDSOndas

ONDSOndas$8.02+0.03%

Questions About PBM

What is the current price of Psyence Biomedical?

Psyence Biomedical is trading at $3.04 per share.

What is the 52-week range for Psyence Biomedical?

Over the past 52 weeks, Psyence Biomedical has traded between $1.92 and $68.53.

How much debt does Psyence Biomedical have?

As of the most recent reporting period, Psyence Biomedical reported total debt of $0.00.

How much cash does Psyence Biomedical have on hand?

Psyence Biomedical reported $7.20M in cash and cash equivalents in its most recent financial results.

What is Psyence Biomedical’s dividend yield?

Psyence Biomedical does not currently have a dividend yield.

Psyence Biomedical(NASDAQ) PBM

Psyence Biomedical Financials at a Glance

PBM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Psyence Biomedical

PBM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Psyence Biomedical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PBM

What is the current price of Psyence Biomedical?

What is the 52-week range for Psyence Biomedical?

How much debt does Psyence Biomedical have?

How much cash does Psyence Biomedical have on hand?

What is Psyence Biomedical’s dividend yield?

Premium Investing Services